Medical researchers are raising concerns about cannabinoid hyperemesis syndrome (CHS), a severe condition marked by cyclical vomiting that affects long-term heavy cannabis users, challenging the perception of marijuana as a universally safe substance that many millennials adopted during the legalization movement.
The condition, sometimes called "scromiting" (screaming and vomiting), has seen increased diagnosis rates as cannabis potency has risen and legal markets have expanded. Emergency room physicians report treating more patients who present with intense abdominal pain and uncontrollable vomiting episodes that can last for hours.
CHS typically develops after years of daily or near-daily cannabis use. Patients often find temporary relief through hot showers or baths, a distinctive symptom that helps physicians differentiate the syndrome from other conditions. The only proven cure is complete cannabis abstinence.
The Potency Problem
Today's legal cannabis products contain significantly higher THC concentrations than marijuana available in previous decades. Dispensary flower commonly tests between 20-30% THC, while concentrates can exceed 90%. This represents a dramatic increase from the 3-8% THC typical of cannabis in the 1990s.
Dr. Cecilia Sorensen, an emergency medicine physician at the University of Colorado, told researchers that she sees CHS cases weekly. "We're dealing with products that are fundamentally different from what people used 20 or 30 years ago," she said in a recent medical journal interview.
The syndrome contradicts cannabis's well-known antiemetic properties. While marijuana effectively reduces nausea for many medical patients, including those undergoing chemotherapy, the paradoxical effect in CHS sufferers remains poorly understood.
Industry Response
The cannabis industry has largely avoided addressing CHS in marketing materials, which typically emphasize therapeutic benefits and minimal side effects. Some medical dispensaries have begun including information about the syndrome in patient education materials, but consumer awareness remains low.
Public health advocates argue that legal cannabis markets need better warning labels and dosage guidance, particularly for high-potency products. Currently, most states require only basic THC content labeling without contextual information about potential risks from heavy use.
The issue comes as the industry pushes for federal rescheduling and expanded medical access. Critics say the lack of comprehensive public health messaging about conditions like CHS undermines claims that legalization prioritizes consumer safety over profit.
What Patients Should Know
Medical professionals recommend that regular cannabis users watch for early warning signs: morning nausea, decreased appetite, and the compulsive need for hot showers. Early intervention and reduced consumption can prevent progression to severe CHS.
Research into the syndrome's mechanisms continues. Some studies suggest that chronic THC exposure may disrupt the endocannabinoid system's regulation of the digestive tract, though definitive answers remain elusive.
For millennials who embraced cannabis as a safer alternative to alcohol or pharmaceutical drugs, CHS represents an uncomfortable reality check. The condition affects an estimated 2-3% of regular cannabis users, though exact prevalence remains unclear due to underdiagnosis and misdiagnosis.
As legal markets mature and longitudinal health data accumulates, public health officials say honest conversations about cannabis risks—including rare but serious conditions like CHS—are essential for responsible regulation and consumer protection.
This article is based on original reporting by slate.com.
